Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients
This study is not yet open for patient recruitment.
Sponsored by: | Department of Veterans Affairs SmithKline Beecham
|
---|---|
Information provided by: | Department of Veterans Affairs |
Purpose
This study aims to determine if treatment with an SSRI antidepressant medication, paroxetine, is associated with cellular calcium response to serotonin, platelet serotonin receptors, and improvement in mood in depressed patients with or without hypertension. It is hypothesized that platelets of hypertensive patients with depressive symptomatology with be hyper-responsive to serotonin. Additionally, treatment with an SSRI antidepressant is expected to produce a down-regulation of the serotonin receptor with an associated reduction in platelet cytosolic calcium response as well as improved mood.
Condition | Treatment or Intervention | Phase |
---|---|---|
Depression Hypertension |
Drug: paroxetine Behavior: ongoing psychological screening |
Phase IV |
MedlinePlus related topics: Depression; High Blood Pressure
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Parallel Assignment, Pharmacodynamics Study
Study start: March 2001;
Study completion: October 2003
Eligibility
Ages Eligible for Study: 25 Years - 65 Years, Genders Eligible for Study: Male
Accepts Healthy Volunteers
Criteria
Subjects for all study groups will be male and between the ages of 25 and 65
Hypertension & Depression Group: Hypertension controlled with an ACE-inhibitor anti-hypertensive; no co-morbid medical conditions known to influence psychological functioning or platelet calcium responses including uncontrolled diabetes, MI or CVA within 6 months of enrollment, secondary hypertension; depression as diagnosed by structured interview and HDRS score of 18; no active participation in another clinical trial; no current suicidal/ homicidal ideation
Hypertension Group: Hypertension controlled with an ACE-inhibitor anti-hypertensive; no co-morbid medical conditions known to influence psychological functioning or platelet calcium responses including uncontrolled diabetes, MI or CVA within 6 months of enrollment, secondary hypertension; no active participation in another clinical trial; no current suicidal/ homicidal ideation
Depression Group: No co-morbid medical conditions known to influence psychological functioning or platelet calcium responses including uncontrolled diabetes, MI or CVA within 6 months of enrollment, secondary hypertension; depression as diagnosed by structured interview and HDRS score of 18; no active participation in another clinical trial; no current suicidal/ homicidal ideation
Location Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |